Search Results 231-240 of 18450 for Relapse

  1. First In Human (FIH) Study of REGN5459 in Patients With Relapsed or Refractory Multiple Myeloma (MM) - Mayo Clinic

    Clinical Trials · First In Human (FIH) Study of REGN5459 in Patients With Relapsed or Refractory Multiple Myeloma (MM) · More about research at Mayo Clinic · Mayo ...

  2. KTX-100 MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma - Mayo Clinic

    KTX-100 MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma ... relapse, treatment refractory disease, ...

  3. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, ...

  4. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, ...

  5. Safety and Efficacy of ALLO-715 and ALLO-647 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) - Mayo Clinic

    Safety and Efficacy of ALLO-715 and ALLO-647 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL). Print details.

  6. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, ...

  7. New therapies, collaborative care improve lymphoma outcomes - Mayo Clinic

    ... relapse and improves rates of local relapse-free and progression-free survival. ... relapsed and refractory DLBCL. Researchers at Mayo Clinic in Florida ...

  8. A Study Comparing Anitocabtagene Autoleucel To Standard Of Care Therapy In Participants With Relapsed/ Refractory Multiple Myeloma (IMMagine-3) - Mayo Clinic

    The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/ ...

  9. Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) - Mayo Clinic

    ... Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). Print ... Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) ...

  10. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, ...